{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:46:30Z","timestamp":1791395190781,"version":"4.3.3"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["50595-2014"],"award-info":[{"award-number":["50595-2014"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"MEST","doi-asserted-by":"publisher","award":["2014M2A2A7055063"],"award-info":[{"award-number":["2014M2A2A7055063"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health & Welfare","award":["HI14C3459"],"award-info":[{"award-number":["HI14C3459"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.radonc.2015.07.003","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T02:39:31Z","timestamp":1438310371000},"page":"165-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["High ratio of programmed cell death protein 1 (PD-1)+\/CD8+ tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy"],"prefix":"10.1016","volume":"117","author":[{"given":"Yu Jin","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaemoon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyubo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui Kyu","family":"Chie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BoKyong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Bun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Whe","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Jue","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung W.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2015.07.003_b0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/13651820801992641","article-title":"Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma","volume":"10","author":"Khan","year":"2008","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.radonc.2015.07.003_b0010","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2015.07.003_b0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3857\/roj.2012.30.4.197","article-title":"Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery","volume":"30","author":"Koh","year":"2012","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.radonc.2015.07.003_b0020","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/000313480407000901","article-title":"Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy","volume":"70","author":"Kelley","year":"2004","journal-title":"Am Surg"},{"key":"10.1016\/j.radonc.2015.07.003_b0025","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1245\/s10434-007-9756-2","article-title":"An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resection","volume":"15","author":"Hernandez","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2015.07.003_b0030","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.radonc.2014.01.003","article-title":"Factors influencing survival outcome for radiotherapy for biliary tract cancer: a multicenter retrospective study","volume":"110","author":"Yoshioka","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.07.003_b0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.radonc.2015.07.003_b0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.radonc.2011.05.054","article-title":"Tumour-infiltrating CD11b+ myelomonocytes and response to fractionated irradiation of human squamous cell carcinoma (hSCC) xenografts","volume":"101","author":"Zaleska","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.07.003_b0045","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.radonc.2010.01.007","article-title":"Prognostic significance of CD24 protein expression in patients treated with adjuvant radiotherapy after radical hysterectomy for cervical squamous cell carcinoma","volume":"95","author":"Sung","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.07.003_b0050","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.radonc.2015.07.003_b0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd3877","article-title":"Advances in targeting cell surface signalling molecules for immune modulation","volume":"12","author":"Yao","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.radonc.2015.07.003_b0060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2015.07.003_b0065","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.radonc.2015.07.003_b0070","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.radonc.2015.07.003_b0075","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2015.07.003_b0080","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.5011","article-title":"Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC) [abstract]","volume":"32","author":"Powles","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.07.003_b0085","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.3064","article-title":"Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies [abstract]","volume":"32","author":"Heery","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.07.003_b0090","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7\u2013H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2015.07.003_b0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","article-title":"Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance","volume":"108","author":"Wu","year":"2006","journal-title":"Acta Histochem"},{"key":"10.1016\/j.radonc.2015.07.003_b0100","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2015.07.003_b0105","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/cncr.25747","article-title":"Overall survival and PD-L1 expression in metastasized malignant melanoma","volume":"117","author":"Gadiot","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2015.07.003_b0110","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.oraloncology.2011.08.007","article-title":"Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma","volume":"47","author":"Cho","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2015.07.003_b0115","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/jso.21376","article-title":"Interaction of B7\u2013H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion","volume":"100","author":"Ye","year":"2009","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.radonc.2015.07.003_b0120","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/cas.12406","article-title":"Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma","volume":"105","author":"Tamai","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.radonc.2015.07.003_b0125","article-title":"Prognostic value of tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in cholangiocarcinoma","volume":"33","author":"Suleiman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.07.003_b0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab Invest"},{"key":"10.1016\/j.radonc.2015.07.003_b0135","doi-asserted-by":"crossref","DOI":"10.3791\/4059","article-title":"Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue","author":"Bigelow","year":"2013","journal-title":"J Vis Exp"},{"key":"10.1016\/j.radonc.2015.07.003_b0140","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.ejca.2013.02.015","article-title":"Clinical impact of programmed cell death ligand 1 expression in colorectal cancer","volume":"49","author":"Droeser","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2015.07.003_b0145","doi-asserted-by":"crossref","first-page":"e29288","DOI":"10.4161\/onci.29288","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer","volume":"3","author":"Schalper","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2015.07.003_b0150","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.25397","article-title":"PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients","volume":"128","author":"Shi","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2015.07.003_b0155","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/modpathol.2010.130","article-title":"Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma","volume":"23","author":"Hsu","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.radonc.2015.07.003_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.07.003_b0165","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","article-title":"PD-1 as a potential target in cancer therapy","volume":"2","author":"McDermott","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2015.07.003_b0170","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2008.17.3567","article-title":"A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers","volume":"26","author":"Camp","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015003400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015003400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T18:10:55Z","timestamp":1691863855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814015003400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0167814015003400"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2015.07.003","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High ratio of programmed cell death protein 1 (PD-1)+\/CD8+ tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2015.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}